fbpx

Biomarkers Drive Advances In Drug Therapy – Massive Bio

Biomarkers Drive Advances In Drug Therapy - Massive Bio

Massive Bio, the company co-founded by Loaiza-Bonilla, for which he serves as Chief Medical Advisor, is helping to advance the field of precision oncology from a patient perspective with its Synergy AI registry, and is collaborating with pharmaceutical companies and healthcare providers to improve education about biomarkers and clinical trial matching. This registry combines genomic/biomarker data with artificial intelligence techniques to remove barriers to access and help justify the cost/benefits to diagnostics and therapeutics, with a major emphasis in clinical trial matching and virtual tumor boards.

Biomarkers drive advances in drug therapy

Media Coverage

Leave a Comment

Your email address will not be published. Required fields are marked *

Previous reading
PRECISION MEDICINE LEADERS’ SUMMIT 2019 – EAST
Next reading
CEO talks at J.P. Morgan Healthcare Conference 2019